Allogeneic Stem Cell Transplantation
37
5
6
16
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.8%
4 terminated out of 37 trials
80.0%
-6.5% vs benchmark
11%
4 trials in Phase 3/4
13%
2 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (37)
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
CIBMTR Research Database
CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD
Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.
Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells
CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia
Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation
Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
Bisantrene for Relapsed /Refractory AML
Physical Exercise Therapy vs Relaxation in Allogeneic Stem Cell Transplantation (PETRA)